BioPharm Insight – Sirona in active discussions to out-license preclinical SGLT-2 antidiabetic candidate – CEO

[at noodls] – by Christine Livoti in New York December 14, 2012 Sirona Biochem (TSX-V:SBM) is in active talks for the licensing of its preclinical antidiabetic candidate, SBM-TFC-039, in Asia and North America, said … more

View todays social media effects on MRK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merck is hiring next, click here to view